News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Arthritis Drug's $1.4 Billion Promise for German Drugmaker 4SC AG (VSC.DU) Hinges on Study, Could Present Itself as Pfizer Inc. (PFE)'s Main Oral RA Competition



5/27/2011 7:23:12 AM

4SC AG (VSC) said study results due by the end of next month may help the German biotechnology company secure a licensing deal for its experimental rheumatoid arthritis medicine, Vidofludimus.

4SC needs a partner to fund the last and most expensive round of human trials required for approval, Chief Executive Officer Ulrich Dauer said in an interview. A possible deal hinges on results from a mid-stage clinical trial that are expected by the end of June, Dauer said. He declined to say how many companies Martinsried, Germany-based 4SC is in talks with, saying the number is “more than two but less than 10.”


Read at Bloomberg


comments powered by Disqus
Bloomberg
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES